Clinical, demographic, and vancomycin time-kill synergism data of 18 patients colonized and infected by multidrug-resistant <i>Acinetobacter baumannii</i>.

<p>Clinical, demographic, and vancomycin time-kill synergism data of 18 patients colonized and infected by multidrug-resistant <i>Acinetobacter baumannii</i>.</p

DNA sequences of oligonucleotides used in polymerase chain reactions to detect carbapenemase and outer-membrane proteins of <i>A</i>. <i>baumannii</i> isolates.

<p>DNA sequences of oligonucleotides used in polymerase chain reactions to detect carbapenemase and outer-membrane proteins of <i>A</i>. <i>baumannii</i> isolates.</p

Determination of minimum inhibitory concentration by microdilution, resistance genes, and molecular profile of six <i>A</i>. <i>baumannii</i> isolates.

<p>Determination of minimum inhibitory concentration by microdilution, resistance genes, and molecular profile of six <i>A</i>. <i>baumannii</i> isolates.</p

Results of the three different methods (FICI, 2-well, and time-kill assay) used to evaluate <i>in vitro</i> synergism of antibiotic combinations against 20 <i>A</i>. <i>baumannii</i> isolates.

<p>Results of the three different methods (FICI, 2-well, and time-kill assay) used to evaluate <i>in vitro</i> synergism of antibiotic combinations against 20 <i>A</i>. <i>baumannii</i> isolates.</p

Minimum inhibitory concentration of antibiotics and resistance mechanisms of 20 <i>A</i>. <i>baumannii</i> isolates.

<p>Minimum inhibitory concentration of antibiotics and resistance mechanisms of 20 <i>A</i>. <i>baumannii</i> isolates.</p

<i>In vitro</i> synergistic effect, according to two different methods (FICI and 2-well) of antimicrobial combinations against 20 isolates of multi-drug resistant <i>Acinetobacter baumannii</i>.

<p><i>In vitro</i> synergistic effect, according to two different methods (FICI and 2-well) of antimicrobial combinations against 20 isolates of multi-drug resistant <i>Acinetobacter baumannii</i>.</p

Time-kill curve of isolates using drugs alone and in combination at 1 x MIC and 0.5 x MIC, respectively, against an <i>A</i>. <i>baumannii</i> isolate.

<p>(A) Isolate 23 –Colistin (16 and 8 mg/L)/Vancomycin (64 and 32mg/L), (B) Isolate 28—Colistin (8 and 4 mg/L)/Rifampicin (4 and 2mg/L), (C) Isolate 1—Imipenem (256 and 128mg/L)/Tigecycline (1 and 0.5mg/L), (D) Isolate 5—Fosfomycin (128 and 64mg/L)/Amikacin (64 and 32mg/L).</p